General Information of Drug Transporter (DT)
DT ID	DTD0452 Transporter Info
Gene Name	SLC6A2
Protein Name	Sodium-dependent noradrenaline transporter
Gene ID	6530
UniProt ID	P23975
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs12708954
Site of GPD	chr16:55697687 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	A=0.1853/928 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Atomoxetine	Drug Info	Attention Deficit Disorder With Hyperactivity	Correlated with the increased drug response in patients (compare with allele C)		[ 1]
Atomoxetine	N.A.	Asthma	Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 1]
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Mirabegron	N.A.	Asthma	Genotype CC is associated with increased clearance of mirabegron in healthy individuals as compared to genotype AC.		[ 2]
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.		[ 1]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine..		[ 1]
Genetic Polymorphism	rs2242446
Site of GPD	chr16:55656513 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.2470/1237 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Venlafaxine	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 3]
Venlafaxine	N.A.	Asthma	Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.		[ 3]
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Individuals with the CC genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.		[ 4]
Venlafaxine	N.A.	Major Depressive Disorder	Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.		[ 3]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
3,4-Methylenedioxymethamphetamine	Drug Info	Posttraumatic Stress Disorder	Correlated with the decreased drug response (compare with genotypes CC + CT)		[ 4]
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT.		[ 4]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.		[ 3]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.		[ 5]
Selective Serotonin Reuptake Inhibitors	N.A.	Asthma	Allele C is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele T.		[ 6]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Individuals with the CT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.		[ 4]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.		[ 3]
Genetic Polymorphism	rs36029
Site of GPD	chr16:55662844 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.3978/1992 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
3,4-Methylenedioxymethamphetamine	Drug Info	Posttraumatic Stress Disorder	Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 4]
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG.		[ 4]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Attention Deficit Disorder With Hyperactivity	Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.		[ 4]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Attention Deficit Disorder With Hyperactivity	Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.		[ 4]
Genetic Polymorphism	rs3785143
Site of GPD	chr16:55661194 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1048/525 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Atomoxetine	Drug Info	Attention Deficit Disorder With Hyperactivity	Correlated with the decreased drug response in patients (compare with allele C)		[ 7]
Methylphenidate	N.A.	Asthma	Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 8]
Atomoxetine	N.A.	Asthma	Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 7]
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 7]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to atomoxetine.		[ 7]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.		[ 7]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atomoxetine	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to treatment with atomoxetine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.		[ 7]
Genetic Polymorphism	rs5569
Site of GPD	chr16:55697923 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	A=0.2334/1169 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methylphenidate	Drug Info	Attention Deficit Disorder With Hyperactivity	Irrelevant to the drug response in patients (compare with Allele G)		[ 5]
Methylphenidate	N.A.	Asthma	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.		[ 5]
Clomipramine	N.A.	Asthma	Allele A is not associated with response to clomipramine in people with Obsessive-Compulsive Disorder as compared to allele G.		[ 10]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.		[ 5]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Methylphenidate	Drug Info	Attention Deficit Disorder With Hyperactivity	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 10]
Antidepressants	N.A.	Asthma	Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.		[ 11]
Methylphenidate	N.A.	Asthma	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.		[ 12]
Methylphenidate	N.A.	Asthma	Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.		[ 13]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.		[ 10]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.		[ 13]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.		[ 5]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.		[ 14]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.		[ 15]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.		[ 16]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.		[ 16]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.		[ 8]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.		[ 8]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.		[ 5]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.		[ 5]
Genetic Polymorphism	rs1861647
Site of GPD	chr16:55694494 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	A=0.2384/1194 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
3,4-Methylenedioxymethamphetamine	Drug Info	Posttraumatic Stress Disorder	Correlated with the increased drug response (compare with genotypes AA + AG)		[ 4]
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG.		[ 4]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Attention Deficit Disorder With Hyperactivity	Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.		[ 4]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Attention Deficit Disorder With Hyperactivity	Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.		[ 4]
Genetic Polymorphism	rs998424
Site of GPD	chr16:55698034 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.7690/1521 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Asthma	Genotype GG is associated with increased clinical benefit to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.		[ 17]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.		[ 5]
Genetic Polymorphism	rs47958
Site of GPD	chr16:55692550 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.6040/1195 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Allele C is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.		[ 4]
Genetic Polymorphism	rs5568
Site of GPD	chr16:55696212 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.7510/1486 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.		[ 5]
Genetic Polymorphism	rs28386840
Site of GPD	chr16:55652906 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.3952/1979 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.		[ 14]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.		[ 14]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.		[ 18]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.		[ 18]
Genotypes AT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methylphenidate	N.A.	Asthma	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.		[ 12]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.		[ 12]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AT or TT genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.		[ 12]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Pediatric patients with the AT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.		[ 12]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Pediatric patients with the TT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.		[ 12]
Genetic Polymorphism	rs3785157
Site of GPD	chr16:55695924 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.7800/1543 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 8]
Genetic Polymorphism	rs7194256
Site of GPD	chr16:55703779 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.8050/1593 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methylphenidate	N.A.	Asthma	Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.		[ 8]
Genetic Polymorphism	rs168924
Site of GPD	chr16:55655632 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.8430/1668 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
3,4-methylenedioxymethamphetamine	N.A.	Asthma	Allele G is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A.		[ 4]
Genetic Polymorphism	rs1362621
Site of GPD	chr16:55654572 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.2350/465 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Asthma	Allele A is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G.		[ 6]
Genetic Polymorphism	rs5564
Site of GPD	chr16:55692063 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.9280/1836 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Asthma	Allele A is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G.		[ 6]
References
1	A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009 Aug;34(9):2135-42.
2	Genetic Variation in. Pharmaceutics. 2024 Aug 17;16(8).
3	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. Am J Psychiatry. 2017 May 1;174(5):468-475.
4	No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA. Eur J Clin Pharmacol. 2018 Mar;74(3):275-283.
5	Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD. Psychiatry Res. 2011 Apr 30;186(2-3):338-44.
6	TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression. Pharmacopsychiatry. 2015 May;48(3):95-103.
7	Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm (Vienna). 2013 Jul;120(7):1127-33.
8	Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 08;84(Pt A):122-128.
9	Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arq Neuropsiquiatr. 2011;69(2B):283-7.
10	Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. Int Clin Psychopharmacol. 2011 Mar;26(2):107-13.
11	Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 01;45:183-94.
12	Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2018 Sep;23(9):1929-1936.
13	Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?. J Child Adolesc Psychopharmacol. 2012 Oct;22(5):343-52.
14	Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects. Sci Rep. 2017 Sep 04;7(1):10391.
15	A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1155-64.
16	Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8.
17	The Role of Gene-Gene Interaction Between. Children (Basel). 2025 May 29;12(6).
18	Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2013 Jun;33(3):356-62.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.